Historical epidemiology of hepatitis C virus (HCV) in selected countries

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11110%2F14%3A10284312" target="_blank" >RIV/00216208:11110/14:10284312 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/61383082:_____/14:#0000271 RIV/00216224:14110/14:00075463 RIV/65269705:_____/14:00062682 RIV/00023001:_____/14:00059020 RIV/75010330:_____/14:00010734

Výsledek na webu

<a href="http://dx.doi.org/10.1111/jvh.12247" target="_blank" >http://dx.doi.org/10.1111/jvh.12247</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1111/jvh.12247" target="_blank" >10.1111/jvh.12247</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Historical epidemiology of hepatitis C virus (HCV) in selected countries

Popis výsledku v původním jazyce

Chronic infection with hepatitis C virus (HCV) is a leading indicator for liver disease. New treatment options are becoming available, and there is a need to characterize the epidemiology and disease burden of HCV. Data for prevalence, viremia, genotype,diagnosis and treatment were obtained through literature searches and expert consensus for 16 countries. For some countries, data from centralized registries were used to estimate diagnosis and treatment rates. Data for the number of liver transplants and the proportion attributable to HCV were obtained from centralized databases. Viremic prevalence estimates varied widely between countries, ranging from 0.3% in Austria, England and Germany to 8.5% in Egypt. The largest viremic populations were in Egypt, with 6358000 cases in 2008 and Brazil with 2106000 cases in 2007. The age distribution of cases differed between countries. In most countries, prevalence rates were higher among males, reflecting higher rates of injection drug use. Dia

Název v anglickém jazyce

Historical epidemiology of hepatitis C virus (HCV) in selected countries

Popis výsledku anglicky

Chronic infection with hepatitis C virus (HCV) is a leading indicator for liver disease. New treatment options are becoming available, and there is a need to characterize the epidemiology and disease burden of HCV. Data for prevalence, viremia, genotype,diagnosis and treatment were obtained through literature searches and expert consensus for 16 countries. For some countries, data from centralized registries were used to estimate diagnosis and treatment rates. Data for the number of liver transplants and the proportion attributable to HCV were obtained from centralized databases. Viremic prevalence estimates varied widely between countries, ranging from 0.3% in Austria, England and Germany to 8.5% in Egypt. The largest viremic populations were in Egypt, with 6358000 cases in 2008 and Brazil with 2106000 cases in 2007. The age distribution of cases differed between countries. In most countries, prevalence rates were higher among males, reflecting higher rates of injection drug use. Dia

Druh

J_x - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)

CEP obor

FE - Ostatní obory vnitřního lékařství

OECD FORD obor

—

Projekt

—

Návaznosti

V - Vyzkumna aktivita podporovana z jinych verejnych zdroju

Rok uplatnění

2014

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Journal of Viral Hepatitis

ISSN

1352-0504

e-ISSN

—

Svazek periodika

21

Číslo periodika v rámci svazku

Supp. 1

Stát vydavatele periodika

GB - Spojené království Velké Británie a Severního Irska

Počet stran výsledku

28

Strana od-do

5-33

Kód UT WoS článku

000333893200002

EID výsledku v databázi Scopus

—